ERBB2 and breast carcinoma: We analyzed the clinicopathological characteristics of recurrent tumors and explored the genomic factors affecting recurrence through gene expression analysis in relapsing and nonrelapsing patients with HER2-positive early breast cancer who received adjuvant trastuzumab.